Fifteen years post-approval of ipilimumab, immunotherapy and targeted therapies continue to redefine cancer treatment at the ASCO conference. The emphasis on personalizing patient care has shown significant promise, allowing oncologists to cure more patients, particularly when therapies are applied in earlier disease stages. Current immunotherapy treatments are effective for only about 25% of patients, leading researchers to innovate with approaches like Trojan horses and bispecific drugs that directly attack tumor cells. The community remains optimistic, showcasing continual advancements in tackling resistant tumors.
“What we are seeing is that applying the innovation of targeted therapies and immunotherapy at earlier stages allows us to cure more patients,” says Ernest Nadal.
“The strategy of mobilizing the body's own immune defenses to fight malignant cells still has plenty of potential,” indicating vibrant ongoing innovation.
Oncologists are increasingly focused on optimizing established immunotherapy treatments, which currently only work for about 25% of cancer patients.
Recent studies highlight the promise of so-called Trojan horses and bispecific drugs, which deliver drugs directly into cancer cells and unify immune cells.
Collection
[
|
...
]